首页 | 本学科首页   官方微博 | 高级检索  
     


Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre,open-label,phase 2a,multiple basket study
Authors:Funda Meric-Bernstam  Herbert Hurwitz  Kanwal Pratap Singh Raghav  Robert R McWilliams  Marwan Fakih  Ari VanderWalde  Charles Swanton  Razelle Kurzrock  Howard Burris  Christopher Sweeney  Ron Bose  David R Spigel  Mary S Beattie  Steven Blotner  Alyssa Stone  Katja Schulze  Vaikunth Cuchelkar  John Hainsworth
Affiliation:1. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA;2. Department of Medicine, Duke University Medical Center, Durham, NC, USA;3. Mayo Clinic, Rochester, MN, USA;4. Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA;5. West Cancer Center, Memphis, TN, USA;6. Francis Crick Institute, London, UK;7. Division of Hematology and Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA;8. Sarah Cannon Research Institute, Nashville, TN, USA;9. Tennessee Oncology, PLLC, Nashville, TN, USA;10. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;11. Washington University School of Medicine, St Louis, MO, USA;12. Genentech Inc, South San Francisco, CA, USA
Abstract:
Keywords:Correspondence to: Prof Funda Meric-Bernstam   Department of Investigational Cancer Therapeutics   University of Texas MD Anderson Cancer Center   Houston   TX 77030   USA
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号